Published in J Clin Lab Anal on January 01, 2009
HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer (2011) 1.95
HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol (2011) 1.50
Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol (2011) 1.36
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer (2011) 1.19
In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem (2014) 1.04
Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol (2013) 0.98
High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer. J Ovarian Res (2012) 0.87
Designing early detection programs for ovarian cancer. Ann Oncol (2011) 0.85
HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival. Int J Mol Sci (2013) 0.85
Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer. Oncol Lett (2013) 0.79
Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer. Medicine (Baltimore) (2015) 0.79
Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women. J Korean Med Sci (2015) 0.79
Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis. Onco Targets Ther (2013) 0.78
MicroRNAs in Gynecological Cancers: Small molecules with big implications. Cancer Lett (2017) 0.76
Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer. Oncol Lett (2016) 0.75
Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective. Ann Transl Med (2017) 0.75
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst (2008) 6.13
Do clinicians decide relying primarily on Bayesians principles or on Gestalt perception? Some pearls and pitfalls of Gestalt perception in medicine. Intern Emerg Med (2014) 3.93
Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients. Arch Pathol Lab Med (2009) 3.84
Very low levels of vitamin D in systemic sclerosis patients. Clin Rheumatol (2010) 2.78
Acquired factor VIII inhibitors. Blood (2008) 2.67
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst (2003) 2.44
Biochemical markers of muscular damage. Clin Chem Lab Med (2010) 2.25
Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension. PLoS Genet (2010) 2.24
NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring) (2008) 2.23
Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med (2010) 2.20
Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care (2007) 2.09
Circulating microRNAs (miRs) for diagnosing acute myocardial infarction: meta-analysis of available studies. Int J Cardiol (2012) 2.07
N-terminal pro-BNP in sclerodermic patients on bosentan therapy for PAH. Rheumatol Int (2007) 2.03
Potential value for new diagnostic markers in the early recognition of acute coronary syndromes. CJEM (2006) 2.01
Preanalytical quality improvement: from dream to reality. Clin Chem Lab Med (2011) 2.01
Preanalytical variability: the dark side of the moon in laboratory testing. Clin Chem Lab Med (2006) 1.85
Recommendations for detection and management of unsuitable samples in clinical laboratories. Clin Chem Lab Med (2007) 1.71
The order of draw: myth or science? Clin Chem Lab Med (2013) 1.66
The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med (2011) 1.65
Serine/threonine kinase 39 is a candidate gene for primary hypertension especially in women: results from two cohort studies in Swedes. J Hypertens (2011) 1.64
Suitability of a transport box for blood sample shipment over a long period. Clin Biochem (2011) 1.64
Opinion paper on innovative approach of biomarkers for infectious diseases and sepsis management in the emergency department. Clin Chem Lab Med (2013) 1.63
Influence of hemolysis on routine clinical chemistry testing. Clin Chem Lab Med (2006) 1.60
Red blood cell distribution width is significantly associated with aging and gender. Clin Chem Lab Med (2014) 1.58
Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation (2002) 1.57
Preanalytical phase--a continuous challenge for laboratory professionals. Biochem Med (Zagreb) (2012) 1.56
Development of a novel, hemolysis-resistant reagent for assessment of α-amylase in biological fluids. Clin Chem Lab Med (2013) 1.54
Laboratory medicine does matter in science (and medicine)… yet many seem to ignore it. Clin Chem Lab Med (2015) 1.53
Biomedical research platforms and their influence on article submissions and journal rankings: an update. Biochem Med (Zagreb) (2012) 1.53
Longitudinal umbilical vein blood flow changes in normal and growth-retarded fetuses. Acta Obstet Gynecol Scand (2002) 1.50
Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol (2008) 1.50
Quality and reliability of routine coagulation testing: can we trust that sample? Blood Coagul Fibrinolysis (2006) 1.50
Postoperative variation of C-reactive protein and procalcitonin in patients with gastrointestinal cancer. Clin Lab (2009) 1.49
Acquired factor V inhibitors: a systematic review. J Thromb Thrombolysis (2011) 1.47
Should women with abnormal serum thyroid stimulating hormone undergo screening for anemia? Arch Pathol Lab Med (2008) 1.45
Together we care: new challenges for global haemophilia treatment centers. Indian J Med Res (2009) 1.44
Red blood cell distribution width: A simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci (2014) 1.44
New ways to deal with known preanalytical issues: use of transilluminator instead of tourniquet for easing vein access and eliminating stasis on clinical biochemistry. Biochem Med (Zagreb) (2011) 1.43
Iron and thrombosis. Ann Hematol (2007) 1.43
The V433M variant of the CYP4F2 is associated with ischemic stroke in male Swedes beyond its effect on blood pressure. Hypertension (2008) 1.42
The baseline serum value of α-amylase is a significant predictor of distance running performance. Clin Chem Lab Med (2015) 1.42
The role of red blood cell distribution width in cardiovascular and thrombotic disorders. Clin Chem Lab Med (2011) 1.42
Routine coagulation tests in newborn and young infants. J Thromb Thrombolysis (2007) 1.42
Phlebotomy issues and quality improvement in results of laboratory testing. Clin Lab (2006) 1.41
Reliability of the thrombin-generation assay in frozen-thawed platelet-rich plasma. Clin Chem (2006) 1.40
The health risks of acute exercise should also matter to internal medicine. Eur J Intern Med (2011) 1.40
Is laboratory medicine a dying profession? Blessed are those who have not seen and yet have believed. Clin Biochem (2010) 1.40
Reduction of unsuitable specimens: a more radical and comprehensive approach is needed. Clin Chim Acta (2010) 1.39
Preanalytical quality improvement. In pursuit of harmony, on behalf of European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) Working group for Preanalytical Phase (WG-PRE). Clin Chem Lab Med (2015) 1.39
The growing impact of publications in haemostasis and thrombosis journals. Thromb Haemost (2007) 1.38
Antenatal care in developing countries: the need for a tailored model. Semin Fetal Neonatal Med (2005) 1.36
Irisin: a new potential hormonal target for the treatment of obesity and type 2 diabetes. J Diabetes (2012) 1.31
Survey of national guidelines, education and training on phlebotomy in 28 European countries: an original report by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) working group for the preanalytical phase (WG-PA). Clin Chem Lab Med (2013) 1.31
Quality standards for sample collection in coagulation testing. Semin Thromb Hemost (2012) 1.29
Vitamin D, thrombosis, and hemostasis: more than skin deep. Semin Thromb Hemost (2012) 1.28
Prothrombin complex concentrates: an update. Blood Transfus (2010) 1.27
Relationship between red blood cell distribution width and kidney function tests in a large cohort of unselected outpatients. Scand J Clin Lab Invest (2008) 1.25
The role of ethnicity, age and gender in venous thromboembolism. J Thromb Thrombolysis (2010) 1.24
Biological variation and reference change values: an essential piece of the puzzle of laboratory testing. Clin Chem Lab Med (2012) 1.22
Laparoscopic radiofrequency thermal ablation: a new approach to symptomatic uterine myomas. Am J Obstet Gynecol (2005) 1.21
Risk management in the preanalytical phase of laboratory testing. Clin Chem Lab Med (2007) 1.20
Mean platelet volume increases with aging in a large population study. Thromb Res (2012) 1.20
ABO blood group, hypercoagulability, and cardiovascular and cancer risk. Crit Rev Clin Lab Sci (2012) 1.20
Impact of the phlebotomy training based on CLSI/NCCLS H03-a6 - procedures for the collection of diagnostic blood specimens by venipuncture. Biochem Med (Zagreb) (2012) 1.20
Acquired factor VIII inhibitors in oncohematology: a systematic review. Crit Rev Oncol Hematol (2008) 1.19